Based on the results of our in vitro experiments, and those of previous studies, the existence of Oct3/4- and Nanog-expressing CSCs in cancer cells in primary lesions is presumed to contribute to development of DNM, at least in part, by enhancing the cell motility and invasiveness of these CSCs. This evidence concerns the gene NANOG and cancer.